This year at the BIO Patient & Health Advocacy Summit we will feature 12 roundtable discussions. This is an opportunity to network with peers from the healthcare community, the roundtable discussions will bring together Summit attendees from different stakeholder organizations, as well as the biotechnology industry, for robust discussions led by roundtable hosts.
Roundtable discussions will be held from 12:00 PM - 1:30 PM in the Salon Rooms and Gallery Ballroom on Thursday, October 25.
Hosted by: Biogen
Think you need a dedicated DC team in order to make lasting policy change? Join this discussion to discuss successes, challenges and best practices for smaller patient advocacy groups to engage in public policy. This discussion will focus on:
- How to focus your policy requests for the biggest impact
- The power of partnerships and broadening your supporters
- How to engage beyond Capitol Hill: regulations and state policy efforts
Discussion Leader: Carolyn Jones, Director, Public Policy and Government Affairs
Access to Care in Medicare Part B
Hosted by: Bristol-Myers Squibb
The Trump Administration has proposed a robust agenda to address prescription drug prices and patient out of pocket costs, including changes to Medicare Part B. HHS is beginning to roll out policies like step therapy and competitive bidding with the aim of promoting competition, but how will these proposals impact patient access to medicines? Join Bristol-Myers Squibb for a discussion of recent changes to Part B and the future landscape for patients.
Discussion Leader: Kelsey Lang, Director, Federal Policy & Government Affairs
Lilly Advocacy Dialogues: Listening Tour – What are Your Priorities?
Hosted by: Lilly
During this interactive conversation, Lilly Advocacy leadership wants to hear from YOU! What are your organization's key policy priorities as we hit the home stretch of the 115th Congress?
Discussion Leader: Michele Oshman, Director, Lilly Federal Advocacy
Advancing Inclusive Research
Hosted by: Genentech
Disparities in clinical research can compromise the promise of precision medicine. At Genentech/Roche, we believe data representative of real world patient populations is required to optimize clinical outcomes, accelerate scientific discovery, and support the promise of personalized healthcare for all patients. This interactive session will examine the role unconscious bias plays in exacerbating disparities in clinical research and why Genentech/Roche is Advancing Inclusive Research in response. Join us as we explore how, together, we can Advance Inclusive Research and catalyze the promise of personalized healthcare for all patients.
Discussion Leader: Gerren Wilson, PharmD, Associate Director, Alliance and Advocacy Relations
Protected Classes in Medicare Part D – Potential Changes on the Horizon?
Hosted by: Gilead Sciences
Discussion Leader: Cookab Hashemi, Director, Federal Government Affairs & Advocacy, Gilead Sciences, Inc.
With potential changes to the six protected classes (epilepsy, mental illness, cancer, HIV-AIDS and organ transplants) in Medicare Part D on the horizon, we would welcome an opportunity to discuss how these proposals will impact the patient advocacy communities in the near future. Join the Gilead Sciences team and others in discussing the proposals in the President’s blueprint and RFI issued by the Department of Health and Human Services (HHS).
Identifying Best Practices in Industry Patient Services: Listening to Advocacy Insights
Hosted by: Servier
Recent legal and public scrutiny on industry patient services programs highlights the importance of developing these programs with the utmost integrity. This session will be implemented to hear from advocates about what makes a successful industry housed patient services program, including discussion on Co-pay and Patient Asisstance efforts and how to bridge the patient services efforts from industry to the valuable services provided by advocacy partners.
Discussion Leader: Wendy Poage, MHA, Head of U.S. Patient Advocacy and Patient Services
Transformative Therapies – Ensuring Patient Access through Reimbursement
Hosted by: BIO
New, innovative treatments – “Transformative Therapies” – provide a significant, durable benefit and value for patient health outcomes, delivery of care, and overall healthcare spending. These innovative drugs and biologicals have the potential to transform the treatment of serious and rare diseases, but reimbursement pathways must be updated to reflect the past pace of innovation. Join us as we discuss ensuring robust reimbursement across sites of care and ensuring timely patient access to these new treatment options.
Discussion Leader: Mallory O’Connor, Director, Healthcare Policy & Federal Programs
State Efforts to Lower Prescription Drug Costs and Control Access to New Therapies
Hosted by: BIO
States have always played a central role in determining patient access to prescription medications, but as new transformative therapies come on the market, they are becoming more aggressive in scrutinizing the cost, value and access to these important therapies. This roundtable will focus on the 2019 state legislative and policy landscape, in particular what states are likely to do with respect to prescription drug pricing legislation, Medicaid waivers and/or plan amendments, and manufacturer co-Pay assistance programs.
Discussion Leader: Patrick Plues, Vice President, State Government Affairs
Value in the Eye of Which Beholder?
Hosted by: BIO
Payors are increasingly turning to value assessment frameworks to measure the “value” of new innovations and medical breakthroughs. These tools can employ complex data and calculations, but as with everything, the devil is in the details. The frameworks payors choose and how they use them in coverage decisions will play an increasingly significant role in patients’ ability to access their medicines. Our discussion will focus on emerging trends in the use of value frameworks and what patients can do to ensure value is measured accurately.
Discussion Leader: Alex Keeton, Director, Policy Research and Analytics
Incorporating the Patient Voice in Drug Development
Hosted by: BIO
Recent legislation has created new directives and opportunities to better incorporate patients’ experiences and perspectives into the drug development and regulatory process, and much progress has been made. The FDA has now released their first draft guidance on Collecting Comprehensive and Representative Input as well as two discussion guides and held a public meeting to inform the next few guidance documents on patient-focused drug development. This discussion will focus on the draft guidance, discussion guides, and recent public meeting and a sharing of thoughts on the progress of this important initiative. Table participants will also be able to discuss data that are currently being collected and used by others, and general questions around patient-focused drug development. Come interact with your colleagues to learn more about what others are doing in the patient-focused drug development space.
Discussion Leader: Danielle Friend, PhD, Director, Science and Regulatory Affairs
Personalized Medicine: “Is This Therapy Going to Work for Me?”
Hosted by: BIO
A customizable healthcare model where medical decisions, practices, and/or products are tailored to the individual patient based on an individual’s genetic profile is no longer a fantasy. This discussion will focus on issues surrounding genetic testing such as access, privacy, targeted therapies, and whether patients should get tested.
Discussion Leader: Phi D. Vu, JD, Director, Diagnostics and Personalized Medicine Policy
Cell and Gene Therapy and Genome Editing
Hosted by: BIO
We have entered a new era of genomic medicine, which makes possible the use of cell and gene therapy products as well as gene editing technologies to treat and cure diseases. This session will discuss the scientific differences between these technologies, their potential and current use in the clinic, and the current regulatory framework in the US, including FDA’s draft framework on Gene Therapy products.
Discussion Leader: Sesquile Ramon, PhD, Director, Science and Regulatory Affairs
*Updated October 18, 2018. Subject to change.